Please use this identifier to cite or link to this item: https://doi.org/10.1016/j.eururo.2010.11.031
Title: NRAMP1 and hGPX1 gene polymorphism and response to bacillus Calmette-Guérin therapy for bladder cancer
Authors: Chiong, E.
Kesavan, A.
Mahendran, R. 
Chan, Y.H.
Sng, J.H. 
Lim, Y.K.
Kamaraj, R.
Tan, T.M.C. 
Esuvaranathan, K.
Keywords: Bacillus Calmette-Guérin
Bladder cancer
Gene polymorphism
Issue Date: Mar-2011
Citation: Chiong, E., Kesavan, A., Mahendran, R., Chan, Y.H., Sng, J.H., Lim, Y.K., Kamaraj, R., Tan, T.M.C., Esuvaranathan, K. (2011-03). NRAMP1 and hGPX1 gene polymorphism and response to bacillus Calmette-Guérin therapy for bladder cancer. European Urology 59 (3) : 430-437. ScholarBank@NUS Repository. https://doi.org/10.1016/j.eururo.2010.11.031
Abstract: Background: The natural resistance-associated macrophage protein 1 (NRAMP1) gene is associated with susceptibility to Mycobacterium tuberculosis in humans and to bacillus Calmette-Guérin (BCG) in mice. The detoxification enzyme, human glutathione peroxidase 1 (hGPX1), is associated with recurrence of bladder cancer (BCa). Objective: To determine whether NRAMP1 and hGPX1 gene polymorphisms correlate with response to BCG immunotherapy for non-muscle-invasive BCa (NMIBC). Design, setting, and participants: DNA was obtained from the peripheral blood of 99 NMIBC patients who were prospectively randomized to receive postresection intravesical BCG (81 mg [n = 50] or 27 mg [n = 19]) or BCG (27 mg) with interferon alpha (IFN-α; n = 30). The median follow-up time was 60 mo. Intervention: Intravesical BCG or BCG-IFN-α. Measurements: Restriction fragment length polymorphism (RFLP) analysis was performed to identify polymorphisms in the NRAMP1 promoter region (GT repeat number) and at position 543 (aspartate [D] and/or asparagine [N] expression) within the NRAMP1 protein (D543N) and position 198 (proline and/or leucine expression) within the hGPX1 protein (Pro198Leu). Data were analyzed using χ2 analysis, multivariate analysis, and Kaplan-Meier curves. Results and limitations: On univariate analysis, the NRAMP1 D543N G:G genotype had decreased cancer-specific survival (CSS; p = 0.036). The hGPX1 CT genotype (Pro-Leu) had decreased recurrence time (p = 0.03) after BCG therapy. On multivariate analysis, patients with the NRAMP1 D543N G:G genotype and allele 3 (GT)n polymorphism had decreased recurrence time (p = 0.014 and p = 0.03) after BCG therapy. The limitation of this study was its small sample size. Conclusions: Polymorphisms of the NRAMP1 and hGPX1 genes may be associated with recurrence of BCa after BCG immunotherapy. © 2010 European Association of Urology. Published by Elsevier B.V. All rights reserved.
Source Title: European Urology
URI: http://scholarbank.nus.edu.sg/handle/10635/109495
ISSN: 03022838
DOI: 10.1016/j.eururo.2010.11.031
Appears in Collections:Staff Publications

Show full item record
Files in This Item:
There are no files associated with this item.

SCOPUSTM   
Citations

17
checked on Jun 21, 2018

WEB OF SCIENCETM
Citations

17
checked on May 1, 2018

Page view(s)

56
checked on Jun 8, 2018

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.